Aug. 20 at 11:06 AM
$ENGN
The bads:
- FAILED on Durability
- Only 1 pipeline
- No diversification
- Medically and commercially failed
- hugely competitive drugs that work
- even if approved will face challenges getting insured or urologists will just use what works
This is packed with special situation funds accumulating huge stakes. Pressured management to preserve cash by firing over 50% of staff so not to bleed the
$258 million.
I see this taken over or liquidated rather than commercilisation
